{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:32:37Z","timestamp":1790674357583,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006339","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T12:36:47Z","timestamp":1489581407000},"page":"e6339","source":"Crossref","is-referenced-by-count":43,"title":["Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine"],"prefix":"10.1097","volume":"96","author":[{"given":"Eva","family":"van Doorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Ben-Yedidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Hassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Visontai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Norley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderik W.","family":"Frijlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-44-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","article-title":"Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines","volume":"59","author":"Cox","year":"2004","journal-title":"Scand J Immunol"},{"key":"R3-44-20210309","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.amjmed.2007.10.040","article-title":"Complications of viral influenza","volume":"121","author":"Rothberg","year":"2008","journal-title":"Am J Med"},{"key":"R4-44-20210309","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12659\/MSM.889671","article-title":"Effectiveness of influenza vaccine in patients on hemodialysis\u2014a review","volume":"19","author":"Mastalerz-Migas","year":"2013","journal-title":"Med Sci Monit"},{"key":"R5-44-20210309","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1097\/CCM.0b013e3181c92eeb","article-title":"Complications of seasonal and pandemic influenza","volume":"38","author":"Rothberg","year":"2010","journal-title":"Crit Care Med"},{"key":"R8-44-20210309","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s11095-008-9559-6","article-title":"Development of stable influenza vaccine powder formulations: challenges and possibilities","volume":"25","author":"Amorij","year":"2008","journal-title":"Pharm Res"},{"key":"R9-44-20210309","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/jps.21523","article-title":"Vaccine adjuvants: current challenges and future approaches","volume":"98","author":"Wilson-Welder","year":"2009","journal-title":"J Pharm Sci"},{"key":"R10-44-20210309","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","article-title":"Toward a universal influenza virus vaccine: prospects and challenges","volume":"64","author":"Pica","year":"2013","journal-title":"Annu Rev Med"},{"key":"R11-44-20210309","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14760584.6.6.939","article-title":"Epitope-based vaccine against influenza","volume":"6","author":"Ben-Yedidia","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"R12-44-20210309","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00216-004-2927-0","article-title":"Detection of influenza virus: traditional approaches and development of biosensors","volume":"381","author":"Amano","year":"2005","journal-title":"Anal Bioanal Chem"},{"key":"R14-44-20210309","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S1473-3099(14)70960-0","article-title":"Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies","volume":"14","author":"Darvishian","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R18-44-20210309","first-page":"10","article-title":"Early estimates of seasonal influenza vaccine effectiveness\u2014United States, January 2015","volume":"64","author":"Flannery","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-44-20210309","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and immunogenicity of Multimeric-001\u2014a novel universal influenza vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J Clin Immunol"},{"key":"R21-44-20210309","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1016\/j.vaccine.2014.08.031","article-title":"Priming by a novel universal influenza vaccine (Multimeric-001)\u2014a gateway for improving immune response in the elderly population","volume":"32","author":"Atsmon","year":"2014","journal-title":"Vaccine"},{"key":"R22-44-20210309","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/JVI.01894-09","article-title":"A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development","volume":"84","author":"Vajo","year":"2010","journal-title":"J Virol"},{"key":"R24-44-20210309","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"key":"R25-44-20210309","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/erv.13.35","article-title":"Immunological assessment of influenza vaccines and immune correlates of protection","volume":"12","author":"Reber","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"R26-44-20210309","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.319.7211.703","article-title":"How to randomise","volume":"319","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"R27-44-20210309","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"R29-44-20210309","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.vaccine.2012.05.049","article-title":"Immune markers and correlates of protection for vaccine induced immune responses","volume":"30","author":"Thakur","year":"2012","journal-title":"Vaccine"},{"key":"R31-44-20210309","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-44-20210309","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jim.2007.03.002","article-title":"Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination","volume":"323","author":"Horton","year":"2007","journal-title":"J Immunol Methods"},{"key":"R33-44-20210309","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"R34-44-20210309","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/CVI.00773-14","article-title":"High-level cellular and humoral immune responses in guinea pigs immunized intradermally with a heat-inactivated VZV vaccine","volume":"22","author":"Sarkadi","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"R35-44-20210309","first-page":"20","article-title":"Preparedness ahead of pandemic outbreaks","volume":"11","author":"Gottlieb","year":"2013","journal-title":"BioProcess Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:31Z","timestamp":1620960331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703170-00044"}},"subtitle":["Phase IIb study protocol"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006339","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}